Log In
Print
BCIQ
Print
Print this Print this
 

MCLA-117

  Manage Alerts
Collapse Summary General Information
Company Merus B.V.
DescriptionHuman bispecific IgG antibody targeting C-type lectin domain family 12 member A (CLEC12A) and CD3
Molecular Target C-type lectin domain family 12 member A (CLEC12A) (CLL1) ; CD3
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today